Tonix Pharmaceuticals (NASDAQ:TNXP) Given Outperform Rating at Noble Financial

Tonix Pharmaceuticals (NASDAQ:TNXP)‘s stock had its “outperform” rating restated by equities research analysts at Noble Financial in a research note issued on Thursday,Benzinga reports. They currently have a $70.00 price objective on the stock. Noble Financial’s target price indicates a potential upside of 203.95% from the stock’s current price.

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a report on Monday, February 10th. They issued a “sell” rating for the company.

Tonix Pharmaceuticals Stock Performance

TNXP opened at $23.03 on Thursday. The stock has a market capitalization of $43.04 million, a price-to-earnings ratio of 0.00 and a beta of 2.23. The company has a fifty day moving average of $18.44 and a 200 day moving average of $19.74. Tonix Pharmaceuticals has a fifty-two week low of $6.76 and a fifty-two week high of $1,146.01. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($9.77) EPS for the quarter, missing the consensus estimate of ($6.23) by ($3.54). The business had revenue of $2.58 million for the quarter, compared to the consensus estimate of $3.20 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. As a group, sell-side analysts forecast that Tonix Pharmaceuticals will post -1762.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Investments LP purchased a new position in Tonix Pharmaceuticals in the 4th quarter worth about $66,000. Point72 Asset Management L.P. purchased a new position in Tonix Pharmaceuticals during the 4th quarter valued at about $526,000. Jane Street Group LLC increased its position in Tonix Pharmaceuticals by 5,932.3% during the 4th quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock valued at $548,000 after purchasing an additional 1,635,119 shares during the period. Northern Trust Corp purchased a new position in Tonix Pharmaceuticals during the 4th quarter valued at about $162,000. Finally, Geode Capital Management LLC increased its position in Tonix Pharmaceuticals by 1,600.1% during the 4th quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock valued at $650,000 after purchasing an additional 1,855,907 shares during the period. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.